DMRA Quick Ratio | DAMORA THERAPEUTICS, INC.

Damora Therapeutics, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

Damora Therapeutics, Inc. quick ratio for the quarter ending 2026-06-30 was 19.62, a 405.14% increase year-over-year.
Damora Therapeutics, Inc. quick ratio for the quarter ending 2026-03-31 was 22.38, a 190.73% increase year-over-year.
Damora Therapeutics, Inc. quick ratio for the quarter ending 2025-12-31 was 12.84, a 8.42% increase year-over-year.
Damora Therapeutics, Inc. quick ratio for the quarter ending 2025-09-30 was 2.9, a 64.03% decline year-over-year.
Damora Therapeutics, Inc. quick ratio for fiscal 2025 was 12.84, a 8.42% increase from fiscal 2024.
Damora Therapeutics, Inc. quick ratio for fiscal 2024 was 11.84, a 108.26% increase from fiscal 2023.
Damora Therapeutics, Inc. quick ratio for fiscal 2023 was 5.69, a 4.87% increase from fiscal 2022.
Damora Therapeutics, Inc. quick ratio for fiscal 2022 was 5.42, a 75.41% decline from fiscal 2021.

Available history: 2019-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2026-06-30	19.62	$540.52M	$27.55M
2026-03-31	22.38	$532.9M	$23.81M
2025-12-31	12.84	$257.62M	$20.07M
2025-09-30	2.9	$7.61M	$2.62M
2025-06-30	3.88	$10.21M	$2.63M
2025-03-31	7.7	$11.94M	$1.55M
2024-12-31	11.84	$14.18M	$1.2M
2024-09-30	8.06	$19.68M	$2.44M
2024-06-30	6.16	$22.86M	$3.71M
2024-03-31	6.29	$27.17M	$4.32M
2023-12-31	5.69	$33.15M	$5.83M
2023-09-30	3.52	$44.18M	$12.56M
2023-06-30	3.5	$52.12M	$14.9M
2023-03-31	3.79	$53.25M	$14.06M
2022-12-31	5.42	$60.22M	$11.11M
2022-09-30	7.8	$69.08M	$8.86M
2022-06-30	10.55	$79.03M	$7.49M
2022-03-31	12.97	$93.6M	$7.21M
2021-12-31	22.05	$100.19M	$4.54M
2021-09-30	17.79	$102.14M	$5.74M
2021-06-30	21.41	$101.81M	$4.76M
2021-03-31	19.95	$110.53M	$5.54M
2020-12-31	29.44	$163.84M	$5.57M
2020-09-30	10.33	$85.57M	$8.28M
2019-12-31	1.45	$11.53M	$7.93M

Annual Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2025-12-31	12.84	$257.62M	$20.07M
2024-12-31	11.84	$14.18M	$1.2M
2023-12-31	5.69	$33.15M	$5.83M
2022-12-31	5.42	$60.22M	$11.11M
2021-12-31	22.05	$100.19M	$4.54M
2020-12-31	29.44	$163.84M	$5.57M
2019-12-31	1.45	$11.53M	$7.93M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
HARROW, INC. (HROW)	United States	$1.240B	-42.77
Avalyn Pharma Inc. (AVLN)	United States	$1.267B
OPKO HEALTH, INC. (OPK)	United States	$1.220B	-15.59
LB PHARMACEUTICALS INC (LBRX)	United States	$1.220B	-10.87
First Tracks Biotherapeutics, Inc. (TRAX)	United States	$1.280B
Bicara Therapeutics Inc. (BCAX)	United States	$1.309B	-10.55
Jaguar Health, Inc. (JAGX)	United States	$1.184B
Latigo Biotherapeutics, Inc. (LTGO)	United States	$1.176B
Tyra Biosciences, Inc. (TYRA)	United States	$1.337B	-12.83
Kardigan, Inc. (KARD)	United States	$1.346B